Rituxan for nephrotic syndrome – pro
Both T- and B-cell immunity are altered in Nephrotic Syndrome.Rituximab has shown best treatment outcomes in patients with steroid-resistant Nephrotic Syndrome, particularly those with Focal Segmental Glomerulosclerosis (FSGS) and young patients who suffer with recurrent FSGS. Successful rituximab therapy can induces prolonged remission and enables discontinuation of other medications without substantially increasing the risk of infections and other serious adverse events. This treatment has been extensively reported and appears to be effective in meta-analyses and reviews.
Ashima Gulati et al, Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome: Multicentric Report
CJASN December 2010 vol. 5 no. 12 2207-2212
Jun Oh; Markus J Kemper, Second-line Options for Refractory Steroid-sensitive and -resistant Nephrotic Syndrome
Disclosures. Expert Rev Clin Pharmacol. 2010;13(4):527-537.
Zhihong Zhao, Guixiang Liao, Yongqiang Li, Shulu Zhou & Hequn Zou, The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: A meta-analysis. Scientific Reports 5, Article number: 8219 (2015)
Kong, W. Y., Swaminathan, R. & Irish, A. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. Int Urol Nephrol 45, 795–802 (2013).